Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
REC-617
i
Other names:
EXS617, EXS-617, REC617, REC 617, REC-617, GTAEXS617, GTAEXS-617, EXS 617
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Recursion Pharma
Drug class:
CDK7 inhibitor
Related drugs:
‹
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
Q901 (1)
AUR102 (0)
EOC237 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
Q901 (1)
AUR102 (0)
EOC237 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=170, Recruiting, Exscientia AI Limited
over 1 year ago
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6) • CD4 (CD4 Molecule)
|
HER-2 negative
|
REC-617
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login